EMDC

Late Friday Afternoon: FDA, Politics, and Scientific Integrity Steve Grossman starts: When my Smartphone delivered an e-mail at 5:12 p.m. on Friday: “FDA approv…,” I knew that FDA had just announced something controversial. All public relations people (including those at FDA) have been taught that late Friday is the time to release stories you don’t [...]

S. 510 – FDA Food Safety Modernization Act – The Small Farms and Businesses Assistance Act Bill Marler summarizes S.510, food safety legislation that passed the House last year and is making its way through the Senate now. The summary of the summary: USDA and FDA jurisdiction over foods remains unchanged Protections for farmers markets, [...]

Drugwonks: University of Michigan Bans CME The University of Michigan has announced it is banning continuing medical education (CME). Many university hospitals offer CME as a product. University physicians also partake in CME. The Fighting Wolverines currently receive about $1,000,000 in such services. And in cash-strapped Michigan that ain’t chump change when libraries are being [...]

10 Things I’m Tired of Hearing About Pharma Social Media I especially liked this part: 8. “There is a need for useful healthcare-related social media tools/content/platforms/communities that pharma companies can help fill.” What? There are so many things wrong with this, I’m not sure where to begin. I’ll just cover two though for the sake [...]

The Beginner’s Guide to Pharma Social Media TONS of resources here. Including a response to the oft-asked “What about adverse events?” question.

FDASM – “Everything about the FDA, Internet, & Social Media” It’s an aggregator of information about the FDA, it’s use of social media, and it’s regulation of social media use by the industries it oversees.

The Indira Gandhi International airport here will soon have a dedicated zone for storing imported and exported pharma products in controlled atmosphere till Customs checking is conducted.

Government Health IT magazine talks about the first steps in FDA’s move towards greater transparency.

Eye on FDA: What We Didn’t Hear at the FDA Part 15 Meeting on Social Media We heard from far too few pharma companies, and far too many bloggers. What was missing? What anyone should be doing in the meantime, what’s the process going forward, and what (if anything) is going on in Europe.

Rich Meyer says pharma marketers don’t even know what to do with the web traffic data they already have much less how to integrate social media into the mix, which is ironic considering how much research goes into pharma industry decision-making.